LigaChem Biosciences, Inc. (LCB) is a clinical stage biopharmaceutical company dedicated to the discovery and development of innovative medicines by leveraging our medicinal chemistry expertise to make conventional biologics more targeted and potent for the benefit of patients with diseases of highly unmet medical needs. We are advancing sustainable pipelines in therapeutic areas within antibiotics, anti-fibrotics, oncology, and antibody-drug conjugate (ADC) platform technology.

LCB’s novel ADC platform technologies overcome the existing limitations of ADCs by imparting a trinity of improved properties, (1) site-specific stable bioconjugation (2) cancer selective linker activation and (3) cancer-selective activation of potent payload, all of which in a significantly broader Therapeutic Window.

Public

Biotech